WHO Treatment Guidelines for Isoniazid-resistant Tuberculosis: Supplement to the WHO Treatment Guidelines for Drug-resistant Tuberculosis

The emergence of drug-resistant TB is a major global health concern, which threatens the ambitious goals and progress set under the End TB Strategy. Isoniazid-resistant TB, which is present in 8% of TB cases worldwide, reduces treatment success in patients treated with the standard 6-month first-line regimen.